Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

What's better than a good thing? More of a good thing. Income investors can find plenty of "good things" in the market these ...

Ubrelvy and Nurtec are prescription medications taken to treat migraines. Though they share similarities, Ubrelvy is for acute treatment, while Nurtec can be taken for immediate symptom relief.